Author: crjfinlayson

July 28, 2022 TORONTO, Canada and RIONEGRO, Colombia (July 28, 2022) – PharmaCielo Ltd. (“PharmaCielo” or the“Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced a

June 6, 2022 The Company has shipped pre-commercial quantities of CBD full spectrum oil containing THC, to support the development of a full spectrum product for the Brazilian market. TORONTO, Canada and RIONEGRO, Colombia (June 6, 2022) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV:

May 30, 2022 The Company expects Revenue to continue to grow – recently shipped 300 kg of CBD Full Spectrum Oil to a Spanish pharmaceutical company, announced entrance into Polish market, and shipments to Germany expected by late 2022. Steadily building pipeline in other key

May 11, 2022 TORONTO, Canada and RIONEGRO, Colombia (May 11, 2022) – PharmaCielo Ltd. (“PharmaCielo” or the“Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), announces today that, further to its

May 6, 2022 Poland is one of the largest cannabis markets in Europe by patient population, with more than 28,000 prescriptions issued to approximately 10,000 patients in the first nine months of 20211. The Company expects to begin shipping to Poland during the first half

April 4, 2022 Builds on the passing of Regulation 227 in February, which implemented legal provisions to enable dried flower export and access to additional opportunities for CBD-based products. PharmaCielo expects to begin exporting dried flower in the second quarter of 2022, with volumes growing

February 20, 2022 PharmaCielo expects to begin exporting dried flower in the first half of 2022, with volumes growing through the remainder of the year. The Company's upstream and downstream scale and quality uniquely position it to be a formidable competitor with psychoactive flower currently

February  14, 2022 The Company will start supplying the German market with three THC-dominant products, with commercial shipments expected to begin in late 2022. This is PharmaCielo’s first sales agreement related to THC products. Represents a significant milestone related to management’s re-focusing of PharmaCielo’s product

February  4, 2022 • PharmaCielo is actively working with, and has recently shipped product to, established companies in Argentina, Brazil, Colombia and Paraguay. • The Company’s sales and technical teams are providing support to these customers as they conduct testing and advance product registrations using

January 3, 2022 All amounts expressed in Canadian dollars unless otherwise noted TORONTO, Canada and RIONEGRO, Colombia (December 31, 2021) – PharmaCielo Ltd. (“PharmaCielo”or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia